## DHR: Danaher Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.2% below STRENGTH zone (3.0-6.0%); PEG 1.85 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($216.41)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Danaher (DHR) Stock on December 1, 2025: Q3 Beat, Legal Probes and Fresh Price Targets â€“ Is the Premium Still Worth Paying?**
- Source: ts2.tech | 20251201T195213 | Somewhat-Bullish | Relevance: 100%
- This article provides an in-depth analysis of Danaher (DHR) stock as of December 1, 2025, covering its Q3 2025 performance, ongoing legal investigations, and updated analyst price targets. It discusses the company's valuation, institutional ownership, insider selling, and the bull versus bear cases, concluding with practical takeaways for investors considering Danaher's premium valuation for its high-quality life-sciences and diagnostics platform.

**2. Schroder Investment Management Group Sells 23,731 Shares of Danaher Corporation $DHR**
- Source: MarketBeat | 20251202T114656 | Somewhat-Bullish | Relevance: 99%
- Schroder Investment Management Group reduced its stake in Danaher Corporation by 8.3%, selling 23,731 shares and retaining 262,124 shares valued at $51.78 million. Institutional ownership of Danaher stands at 79.05%, while insiders have sold a combined 30,248 shares over the last three months, though still owning 11.10% of the stock. Analysts largely maintain a "Moderate Buy" rating with an average price target of $243.39, despite some recent price target adjustments.

**3. M.D. Sass LLC Boosts Stake in Danaher Corporation $DHR**
- Source: MarketBeat | 20251202T124631 | Somewhat-Bullish | Relevance: 99%
- M.D. Sass LLC significantly increased its stake in Danaher Corporation by 13.8%, now holding 356,654 shares valued at $70.45 million, making it their sixth-largest position. Despite insider selling activity totaling $6.61 million over 90 days, Danaher reported an EPS beat of $1.89 against an estimated $1.72 on $6.05 billion revenue, and analysts maintain a "Moderate Buy" rating with an average target price of $243.39.

**4. Bronstein, Gewirtz & Grossman, LLC Encourages Danaher Corporation (DHR) Stockholders to Inquire about Securities Investigation**
- Source: KLAS 8 News Now | 20251202T110000 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Danaher Corporation (NYSE: DHR) securities who bought prior to April 21, 2022, and continue to hold them. The investigation focuses on whether Danaher and its officers/directors engaged in corporate wrongdoing. The firm encourages affected investors to contact them to assist with the investigation.

**5. Danaher initiated with an Overweight at Morgan Stanley, named Top Pick in group**
- Source: MSN | 20251202T035348 | Bullish | Relevance: 99%
- Morgan Stanley initiated coverage of Danaher with an Overweight rating, designating it a "Top Pick" within its coverage group. The firm highlighted Danaher's strong financial profile, including its robust R&D pipeline and impressive FCF conversion, as reasons for its positive outlook. Morgan Stanley projects significant upside potential for Danaher's stock over the next 12 months.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $265 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $270 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 10 ($75.99M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 8.6% (+0.2%)
- Blackrock Inc.: 7.4% (+0.1%)
- JPMORGAN CHASE & CO: 5.3% (+404.7%)
- State Street Corpora: 3.9% (-0.3%)
- Capital Internationa: 2.4% (+1.9%)

### Key Risks

1. Heavy insider selling: $76M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.85 elevated, pricing in significant growth expectations. Forward P/E 26.9x stretched relative to 9% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($76.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $165.0B |
| Beta | 0.92 |
| 52W Range | $171.00 - $258.23 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.85 |
| Forward P/E | 26.9 |
| Current P/E | 29.4 |
| YoY Growth | 9.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.7% to -2.2% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.2pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.23% (CS: 33) | Weak |
| RSI_14 | 60.1 | Neutral |
| MACD Histogram | 0.01 | Bullish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 1.065x | Above |
| vs SMA200 | 1.118x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $226.59
- **Stop Loss:** $216.41 (4.5% risk)
- **Target:** $236.77 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 98
- **Position Value:** $22,205.82
- **Portfolio %:** 22.21%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-01-28 (Est: $2.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.72 | $1.89 | +9.8% |
| 2025Q2 | $1.64 | $1.80 | +9.5% |
| 2025Q1 | $1.64 | $1.88 | +14.4% |
| 2024Q4 | $2.16 | $2.14 | -1.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*